These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29471865)

  • 21. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire.
    Pépin J; Milord F; Meurice F; Ethier L; Loko L; Mpia B
    Trans R Soc Trop Med Hyg; 1992; 86(3):254-6. PubMed ID: 1412646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NECT trial: more than a small victory over sleeping sickness.
    Opigo J; Woodrow C
    Lancet; 2009 Jul; 374(9683):7-9. PubMed ID: 19559477
    [No Abstract]   [Full Text] [Related]  

  • 23. Human African Trypanosomiasis in Emigrant Returning to China from Gabon, 2017.
    Wang X; Ruan Q; Xu B; Gu J; Qian Y; Chen M; Liu Q; Lu Q; Zhang W
    Emerg Infect Dis; 2018 Feb; 24(2):400-404. PubMed ID: 29350158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unusual MRI Findings in African
    Boukobza M; Lariven S; Houzé S; Laissy JP
    Am J Trop Med Hyg; 2020 Jan; 102(1):5-6. PubMed ID: 31971136
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment options for second-stage gambiense human African trypanosomiasis.
    Eperon G; Balasegaram M; Potet J; Mowbray C; Valverde O; Chappuis F
    Expert Rev Anti Infect Ther; 2014 Nov; 12(11):1407-17. PubMed ID: 25204360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo.
    Balasegaram M; Harris S; Checchi F; Hamel C; Karunakara U
    Bull World Health Organ; 2006 Oct; 84(10):777-82. PubMed ID: 17128357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes.
    Balasegaram M; Young H; Chappuis F; Priotto G; Raguenaud ME; Checchi F
    Trans R Soc Trop Med Hyg; 2009 Mar; 103(3):280-90. PubMed ID: 18947846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.
    Jansson-Löfmark R; Na-Bangchang K; Björkman S; Doua F; Ashton M
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1299-307. PubMed ID: 25512417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness.
    Milord F; Pépin J; Loko L; Ethier L; Mpia B
    Lancet; 1992 Sep; 340(8820):652-5. PubMed ID: 1355219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go.
    Chappuis F
    Clin Infect Dis; 2007 Dec; 45(11):1443-5. PubMed ID: 17990226
    [No Abstract]   [Full Text] [Related]  

  • 31. The treatment of human African trypanosomiasis.
    Pépin J; Milord F
    Adv Parasitol; 1994; 33():1-47. PubMed ID: 8122565
    [No Abstract]   [Full Text] [Related]  

  • 32. The evolving spectrum of human African trypanosomiasis.
    Kennedy PGE
    QJM; 2024 Jun; 117(6):391-395. PubMed ID: 38065835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis.
    Franco JR; Simarro PP; Diarra A; Ruiz-Postigo JA; Samo M; Jannin JG
    Res Rep Trop Med; 2012; 3():93-101. PubMed ID: 30100776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo.
    Balasegaram M; Harris S; Checchi F; Ghorashian S; Hamel C; Karunakara U
    Bull World Health Organ; 2006 Oct; 84(10):783-91. PubMed ID: 17128358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study.
    Priotto G; Pinoges L; Fursa IB; Burke B; Nicolay N; Grillet G; Hewison C; Balasegaram M
    BMJ; 2008 Mar; 336(7646):705-8. PubMed ID: 18321960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis.
    Babokhov P; Sanyaolu AO; Oyibo WA; Fagbenro-Beyioku AF; Iriemenam NC
    Pathog Glob Health; 2013 Jul; 107(5):242-52. PubMed ID: 23916333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A seven days course of eflornithine for relapsing Trypanosoma brucei gambiense sleeping sickness.
    Khonde N; Pépin J; Mpia B
    Trans R Soc Trop Med Hyg; 1997; 91(2):212-3. PubMed ID: 9196773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.
    Bisser S; N'Siesi FX; Lejon V; Preux PM; Van Nieuwenhove S; Miaka Mia Bilenge C; Būscher P
    J Infect Dis; 2007 Feb; 195(3):322-9. PubMed ID: 17205469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in sleeping sickness therapy.
    Van Nieuwenhove S
    Ann Soc Belg Med Trop; 1992; 72 Suppl 1():39-51. PubMed ID: 1417168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
    Sokolova AY; Wyllie S; Patterson S; Oza SL; Read KD; Fairlamb AH
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2893-900. PubMed ID: 20439607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.